Roxane Laboratories, Inc. Updated Launch of Calcium Acetate Capsules, 667mg

COLUMBUS, Ohio, Oct. 22 /PRNewswire/ -- Last week, Roxane Laboratories, Inc. launched its calcium acetate capsules, 667mg. Since the October 15 exclusive launch of this product, Roxane Laboratories, Inc., has experienced tremendous demand.

Roxane Laboratories' calcium acetate capsules, 667mg are the only AB rated generic alternative to PhosLo(R) (calcium acetate) capsules, used in the treatment of high levels of phosphate in patients with chronic renal failure. Annual sales of PhosLo(R) (calcium acetate) capsules are approximately $84.8 million(1).

Full prescribing information for calcium acetate capsules, 667mg is available on the Roxane Laboratories website at www.Roxane.com or upon request by calling Roxane Laboratories Technical Product Information hotline at 1-800-962-8364.

About Roxane Laboratories, Inc.

Roxane Laboratories is located in Columbus, OH in a modern 500,000 square foot manufacturing and laboratory facility. The facility spans 70 acres and currently employs over 1,000 people. Currently, Roxane Laboratories markets over 75 medications in nearly 250 package sizes, focusing on an expanding line of Multisource pharmaceutical products including: bulk and unit-dose liquids and solids; coated, sustained-release and controlled release tablets; nasal sprays, cytotoxics and CII narcotics.

Roxane Laboratories, Inc., is a subsidiary of Boehringer Ingelheim Corporation, based in Ridgefield, CT and a member of the Boehringer Ingelheim group of companies.

About Boehringer Ingelheim

Boehringer Ingelheim Corporation based in Ridgefield, CT, is the US headquarters to seven subsidiaries and a member of the Boehringer Ingelheim group of companies.

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 135 affiliates in 47 countries and approximately 39,800 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

In 2007, Boehringer Ingelheim posted net sales of US $15.0 billion (10.9 billion euro) while spending approximately one-fifth of net sales in its largest business segment, Prescription Medicines, on research and development.

For more information on Boehringer Ingelheim, please visit http://us.boehringer-ingelheim.com.

(1) IMS MAT dollar sales ending 6/2008

PhosLo(R) is a registered trademark of Fresenius Medical Care.

CONTACT: Angela Chirico, +1-614-272-4774,
Angela.Chirico@boehringer-ingelheim.com, for Roxane Laboratories

Web site: http://www.Roxane.com/
http://www.boehringer-ingelheim.com/

Back to news